AKAP150-mediated TRPV1 sensitization is disrupted by calcium/calmodulin by Chaudhury, Sraboni et al.
RESEARCH Open Access
AKAP150-mediated TRPV1 sensitization is
disrupted by calcium/calmodulin
Sraboni Chaudhury
1, Manjot Bal
2, Sergei Belugin
3, Mark S Shapiro
2 and Nathaniel A Jeske
1,4*
Abstract
Background: The transient receptor potential vanilloid type1 (TRPV1) is expressed in nociceptive sensory neurons
and is sensitive to phosphorylation. A-Kinase Anchoring Protein 79/150 (AKAP150) mediates phosphorylation of
TRPV1 by Protein Kinases A and C, modulating channel activity. However, few studies have focused on the
regulatory mechanisms that control AKAP150 association with TRPV1. In the present study, we identify a role for
calcium/calmodulin in controlling AKAP150 association with, and sensitization of, TRPV1.
Results: In trigeminal neurons, intracellular accumulation of calcium reduced AKAP150 association with TRPV1 in a
manner sensitive to calmodulin antagonism. This was also observed in transfected Chinese hamster ovary (CHO)
cells, providing a model for conducting molecular analysis of the association. In CHO cells, the deletion of the C-
terminal calmodulin-binding site of TRPV1 resulted in greater association with AKAP150, and increased channel
activity. Furthermore, the co-expression of wild-type calmodulin in CHOs significantly reduced TRPV1 association
with AKAP150, as evidenced by total internal reflective fluorescence-fluorescence resonance energy transfer (TIRF-
FRET) analysis and electrophysiology. Finally, dominant-negative calmodulin co-expression increased TRPV1
association with AKAP150 and increased basal and PKA-sensitized channel activity.
Conclusions: the results from these studies indicate that calcium/calmodulin interferes with the association of
AKAP150 with TRPV1, potentially extending resensitization of the channel.
Background
The transient receptor potential vanilloid type1 (TRPV1)
demonstrates a key role in injury and inflammatory con-
ditions that can precipitate allodynia and hyperalgesia
[1,2]. TRPV1 is a ligand-gated ion channel belonging to
the transient receptor potential (TRP) family and is pri-
marily expressed in peripheral c- and Aδ fibers [3].
TRPV1 participates in physical and chemical pain-evoked
signal transduction, as it is activated by capsaicin, nox-
ious heat (>42°C, [2]), low pH [4], cannabinoids including
anandamide [5,6], and certain lipids [7]. TRPV1 contains
multiple phosphorylation sites that are modified by pro-
tein kinase C (PKC) [8-10] and protein kinase A (PKA)
[11-13] that play an important role in its sensitivity to
agonist-directed activation. Additionally, TRPV1 interacts
with a number of modulatory proteins including cytoske-
leton proteins [14], the plasma membrane-associated
protein Pirt [15] and the scaffolding protein A-kinase
anchoring protein 79/150 (AKAP79 is the human ortho-
log, AKAP150 is the rodent ortholog) [16-19]. Impor-
tantly, AKAP150 modulates PKA- and PKC-mediated
phosphorylation and mediates the activity of the TRPV1
receptor [16,17]. However, it is unclear whether certain
signaling mechanisms mediate the association of TRPV1
with AKAP150.
TRPV1 is a cation-permeable channel whose activa-
tion results in Ca
2+ influx, resulting in membrane depo-
larization [2]. The rise in intracellular calcium
stimulates several signaling cascades that can affect
TRPV1 activity, including the calcineurin/protein phos-
phatase 2B (PP2B) pathway [20]. Following calcium-
mediated activation of calcineurin, the phosphatase is cap-
able of de-phosphorylating and de-sensitizing TRPV1 [21].
Indeed, both the chelation of extracellular calcium or co-
treatment with calcineurin inhibitors reduce Ca
2+-depen-
dent desensitization of TRPV1 in cultured DRG neurons
[22]. Previous studies on the amino acid sequence of
TRPV1 have identified both N- and C-terminal sites
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terminal binding site has demonstrated more significance
in the tachyphylactic desensitization of TRPV1 [24]. Adja-
cent to the C-terminal binding site, Zhang et al. proposed
a binding site for AKAP150, producing a 13-mer peptide
corresponding to the TRPV1 C-terminal sequence (AA
736-749 of human TRPV1) capable of blocking association
of the scaffolding protein and the receptor channel [19].
Considering the large size of AKAP150 (150 kDa), it is
possible that a signaling process that associates with the
C-terminal end of TRPV1 may occlude association of the
receptor channel with AKAP150.
In the present study, we investigate the potential role
that calcium/calmodulin has on AKAP150 association
with TRPV1. Using biochemical, molecular, and imaging
techniques, we sought to determine whether the primary
mechanism that drives tachyphylactic desensitization of
TRPV1, also actively dissociates AKAP150 from the
receptor channel. Such a mechanism would provide a
calcium-dependent regulatory process that preserves
TRPV1 channel desensitization as to not over-activate
nociceptive neurons.
Results and Discussion
The association of AKAP150 and TRPV1 in the plasma
membrane is calcium sensitive
We have previously demonstrated AKAP150 association
with TRPV1 in the plasma membrane of cultured tri-
geminal ganglia (TG, [16]. To determine the calcium-
sensitivity of this association, we employed the calcium
ionophore A23187 to induce calcium influx. In cultured
TG neurons, A23187 treatment (1 μM, 10 min)
decreased AKAP150 association with TRPV1 in the
plasma membrane (Figure 1A-B), but did not effect
plasma membrane-expression of either the scaffolding
protein or the receptor channel (Figure 1C). These
results suggest that a minor fraction of plasma-mem-
brane localized AKAP150 associates with TRPV1, as
Figure 1 TRPV1 association with AKAP150 is calcium sensitive. (A) Co-immunoprecipitation and Western blot analysis of TRPV1 and
AKAP150 following A23187 (1 μM, 10 min) in trigeminal neurons. (B) Quantified densitometry of data represented in (A), n = 4. (C) Plasma
membrane expression of TRPV1 and AKAP150 does not change following A23187 exposure. (D) Quantified densitometry of data represented in
(C), n = 3. (E) Co-immunoprecipitation of TRPV1 and AKAP150 from cultured TG neurons pretreated with A23187 and/or W-7 (calmodulin
antagonist (100 μM; 30 min). (F) Quantified densitometry of data represented in (E), n = 5. Significance to vehicle treatment determined by two-
tailed, paired t-test, **p < 0.01.
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besides TRPV1 (for review, see [26]). The calcium-
dependent signaling molecule calmodulin (CaM) med-
iates several post-translational events upon TRPV1
[24,27,28], prompting us to investigate whether this
molecule is directing the calcium-sensitive association of
AKAP150 and TRPV1. To discern this, we pre-treated
cultured TG neurons with the CaM antagonist W-7
(100 μM, 30 min) prior to A23187 treatment, and
observed a reversal of the calcium-dependent dissocia-
tive effect on AKAP150 and TRPV1 (Figure 1D). These
data suggest that calcium-mediated dissociation of
AKAP150 and TRPV1 involves the calcium-sensitive sig-
naling protein CaM in cultured TG.
Role of intracellular calcium in the association of
AKAP150 and TPRV1
We next assessed the role of calcium in the association
of AKAP150 and TRPV1 in a transfected, serum-starved
CHO cell model. Unlike TG neurons, A23187 treatment
did not yield significant changes in AKAP150 associa-
tion with TRPV1 in plasma membrane homogenates
(Figure 2A-B). However, BAPTA-AM-driven chelation
of intracellular calcium resulted in a significant increase
in AKAP150 association with TRPV1, indicating that
similar to cultured TG, intracellular calcium interferes
with the association of the scaffolding protein and
receptor channel in the plasma membrane compart-
ment. Following Western blot analysis of co-immuno-
precipitates, TRPV1 activity was monitored by calcium
imaging, to determine whether calcium-directed changes
in AKAP150 association with TRPV1 would effect cap-
saicin sensitivity of TRPV1. As shown in Figure 2C-D,
BAPTA-AM pre-treatment not only increased basal
TRPV1 activity, but also significantly increased PKA-
mediated sensitization (8-Br-cAMP, 10 μM, 30 sec) of
the receptor channel. Furthermore, A23187 pre-treat-
ment of CHO cells reduced the significant effects of 8-
Figure 2 Intracellular calcium effects TRPV1 and AKAP150 association and TRPV1 activity. (A) Co-immunoprecipitation and Western blot
analysis from CHO cells following BAPTA-AM (50 μm, 10 min) or A23187 (1 μm, 10 min). (B) Quantified densitometry of co-immunoprecipitation
normalized to total TRPV1 expression. (C) Representative calcium-imaging traces of capsaicin (CAP)-stimulated (50 nm, 30 sec) intracellular Ca
2+
accumulation from CHO cells expressing TRPV1 and AKAP150. Cells pretreated with vehicle (H20, veh), BAPTA-AM (50 μm, 10 min) or A23187 (1
μm,10 min) followed by 8-Br-cAMP (10 μm, 30 sec) administration. (D) Data represented in C are quantified as ΔF340/F380, mean ± SEM shown, n
shown for each treatment paradigm. Significance determined by one-way ANOVA with Bonferroni correction, NS = no significance, *** p < 0.001.
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cells. Taken together with co-immunoprecipitation
results, the functional association of AKAP150 with
TRPV1 and its ability to direct PKA-mediated sensitiza-
tion of TRPV1 [16,18,19] are sensitive to intracellular
calcium.
Role of calmodulin in AKAP150-mediated TRPV1 activity
Previous studies have demonstrated that CaM modu-
lates TRPV1 and can affect channel activity in Ca
2
+-dependent manner [24,25]. To determine the role of
CaM in AKAP150-dependent PKA-sensitization of
TRPV1 in serum-starved CHO cells, we pre-treated
transfected cells with the CaM antagonist W-7 (100 μM,
30 min), followed by 8-Br-cAMP (10 μM, 30 sec), to
determine the effects on TRPV1 activation by capsaicin
(CAP, 50 nM, 30 sec) using calcium imaging. As
reported previously [16,18,19], 8-Br-cAMP treatment
sensitized the CAP-response in AKAP150 and TRPV1-
expressing cells (Figure 3A, C). Importantly, W-7 pre-
treatment significantly increased the PKA-sensitized
CAP-response in cells treated with 8-Br-cAMP, over
those treated with vehicle and 8-Br-cAMP (Figure 3C).
Next, we utilized a cell-permeable calcineurin autoinhi-
bitory peptide (CAIP) to determine whether the effects
of W-7 in this study were due to the subsequent inhibi-
tion of calcineurin-directed changes in TRPV1 activity.
As demonstrated in Figure 3B-C, CAIP did not signifi-
cantly effect any changes in TRPV1 activity induced by
W-7-mediated inhibition of CaM. Importantly, CAIP
also failed to significantly effect basal vehicle or 8-Br-
cAMP-stimulated activity. Indeed, W-7 still significantly
increased the PKA-sensitized CAP-response in cells
treated with 8-Br-cAMP, over those treated with CAIP
and 8-Br-cAMP. These results indicate that the effects
of CaM inhibition on AKAP150 association with and
Figure 3 Calmodulin inhibition increases AKAP150- mediated sensitization of TRPV1 activity. (A-B) Representative traces of CAP-
stimulated (50 nM, 30 sec) intracellular Ca
2+ accumulation from CHO cells expressing TRPV1 and AKAP150. Cells pretreated with vehicle (H20,
veh) or W-7 (100 μM) or CAIP (50 μM) for 30 min followed by 8-Br-cAMP (10 μm, 30 sec) administration. (C) Data represented in A are quantified
as ΔF340/F380, mean ± SEM shown, n shown for each treatment paradigm. The white § indicates sample groups pre-treated with calcineurin
auto-inhibitory peptide (CAIP). Significance determined by one-way ANOVA with Bonferroni correction, *p < 0.01, ***p < 0.001.
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CaM.
Deletion of calmodulin binding-sites on TRPV1 influences
AKAP150 association with TRPV1
The TRPV1 amino acid sequence contains two con-
firmed CaM binding sites: one on the intracellular C-
terminus [24] and one on the intracellular N-terminus
[23]. To determine the relevance of CaM binding to
TRPV1 as an inhibitor of AKAP150 association with the
receptor channel, we mutationally deleted either the C-
terminal or N-terminal CaM binding sequences in
TRPV1 cDNA. Then, we compared the association of
the mutants and full-length TRPV1 with AKAP150, and
determined how the sequence deletions affect aspects of
TRPV1 activity. As depicted in Figure 4A, deletion of
the C-terminal CaM binding sequence (TRPV1 C CaM)
resulted in greater co-immunoprecipitation of the
mutant TRPV1 with AKAP150 over the N-terminal
deletion mutant (TRPV1ΔN CaM) or full-length
TRPV1. The fidelities of the mutations were confirmed
by looking at their effects on the tachyphylactic desensi-
tization of TRPV1 by repeated CAP-applications. The
deletion of the C-terminal CaM binding site of TRPV1
Figure 4 Deletion of calmodulin-binding sites on TRPV1 effects TRPV1 and AKAP150 association. (A) Co-immunoprecipitation and
Western-blot analysis of AKAP150 with TRPV1, TRPV1ΔN CaM (TRPV1 mutant with deleted N-terminal calmodulin binding site) or TRPV1ΔC CaM
(TRPV1 mutant with deleted C-terminal calmodulin binding site) in CHO cells. Results are representative of 4 independent trials. (B) Quantified
densitometry of data represented in (A), n = 3. Significance with AKAP150 + TRPV1 transfection paradigm determined by determined by two-
tailed, paired t-test, **p < 0.01. (C) Data from calcium-imaging traces of capsaicin (CAP)-stimulated (50 nM, 30 sec) intracellular Ca
2+
accumulation from CHO cells expressing AKAP150 and TRPV1, TRPV1ΔN CaM TRPV1ΔC CaM are quantified as ΔF340/F380, mean ± SEM shown, n
shown for each treatment/transfection paradigm. White asterisks indicate significance between AKAP150 and TRPV1ΔCCaM expressing cells and
AKAP150 and TRPV1 expressing cells. (D) Data in C are transformed to illustrate percent desensitization. Significance determined by one-way
ANOVA with Bonferroni correction, NS = no significance, ***p < 0.001.
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of TRPV1, as shown in Figure 4B-D, similar to other
reported findings [24]. However, the effect of the C-
terminal CaM binding site deletion could also be driven
by the increased association of AKAP150 with the
mutant TRPV1, thereby allowing for sensitization of the
channel. This is evident in Figure 4C, as the basal CAP-
response in TRPV1ΔC CaM was significantly higher
than for full-length TRPV1 or TRPV1ΔNC a M .T h i s
also effected the percent desensitization reported in Fig-
ure 4D, as increased AKAP150 association with
TRPV1ΔC CaM would drive increased CAP-response.
The deletion of the C-terminal CaM binding site of
TRPV1 increased PKA-mediated CAP-responsiveness of
TRPV1 in CHO cells co-expressing AKAP150 (Figure
5). Although there were significant changes in basal and
8-Br-cAMP-stimulated CAP-activity of TRPV1 (Figure
5B), there were no significant changes in percent sensiti-
zation from AKAP150 and full-length TRPV1 expressing
cells (Figure 5C). These data suggest that deletion of the
C-terminal CaM binding site of TRPV1 increases
AKAP150 association.
Calmodulin co-expression disrupts AKAP150 and TPRV1
association
We next sought to determine whether the co-expression
of calmodulin effects the association of AKAP150 and
TRPV1 at the plasma membrane, using FRET measured
by the donor-dequenching method under TIRF illumi-
nation. CHO cells were co-transfected with CFP-
TRPV1, AKAP150-YFP and either wild type CaM
(wtCaM) or a dominant-negative CaM (DNCaM, with
all four Ca
2+-binding sites mutated, preventing CaM
from binding Ca
2+ [29-31]). In Figure 6, TIRF/FRET
analysis demonstrates a significant decrease in the per-
centage of CFP emission in CHO cells over-expressing
CFP-TRPV1, AKAP150-YFP, and wtCaM, versus those
cells co-expressing empty vector (pcDNA3) or DNCaM
(p < 0.05, one-way ANOVA, Bonferroni correction).
The TIRF/FRET findings were similar to the effects that
wtCaM and DNCaM had on AKAP150 association with
TRPV1 by co-immunoprecipitation (Figure 7A-B). Sig-
nificantly more AKAP150 associated with TRPV1 in the
presence of DNCaM compared to cells co-transfected
with empty vector, highlighting the inhibitory role that
the calcium-signaling molecule plays in the association
of AKAP150 and TRPV1. Whole-cell electrophysiology
was utilized to determine the functional extent of
AKAP150 association with TRPV1, using 8-Br-cAMP
treatment to stimulate PKA-directed sensitization of
TRPV1, which is AKAP150-dependent [13,16,18,19]. In
Figure 7C-F, the co-expression of wtCaM with TRPV1
a n dA K A P 1 5 0i n h i b i t e dP K A - m e d i a t e ds e n s i t i z a t i o no f
TRPV1 following 8-Br-cAMP pre-treatment, suggesting
reduced AKAP150 association with the receptor chan-
nel. In contrast, DNCaM co-expression allowed PKA-
mediated sensitization of TRPV1. Thus, the presence of
CaM disrupts AKAP150 and TRPV1 association and
any subsequent AKAP150-mediated TRPV1 sensitization
by PKA.
Figure 5 Deletion of calmodulin-binding site on TRPV1 does
not affect AKAP150-mediated TRPV1 activity. (A) Representative
calcium-imaging traces of CAP-stimulated (50 nM, 30 sec)
intracellular Ca
2+ accumulation from CHO cells expressing AKAP150
and TRPV1, TRPV1ΔN CaM or TRPV1ΔC CaM following vehicle (Veh,
H20) or 8-Br-cAMP (8-Br-cAMP, 10 μM, 30 sec) pre-treatment. (B)
Data represented in(A) are quantified as ΔF340/F380, mean ± SEM
shown, n shown for each treatment/transfection paradigm. Black
asterisks indicate significance between indicated groups. White
asterisks indicate significance between marked treatment group and
AKAP150 and TRPV1 expressing treatment groups (Veh-treated
AKAP150 + TRPV1 ΔC CaM v. Veh-treated AKAP150 + TRPV1, for
example). (C) Data in B are transformed to illustrate percent
sensitization following 8-Br-cAMP pre-treatment. Significance
determined by one-way ANOVA with Bonferroni correction, *p <
0.05, ***p < 0.001.
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The calcium sensor and signal transducer CaM, serves
multiple roles in a variety of cell types, often translocat-
ing from one cellular compartment to another in
response to increases in intracellular calcium [32]. In
the case of TRPV1, CaM serves to mediate calcium-
dependent events that include calcineurin-dependent
de-phosphorylation and desensitization of TRPV1
[24,25], as well as CaM Kinase II-dependent
phosphorylation and sensitization of the receptor chan-
nel [27,28]. In this study, we sought to determine the
role of calcium and/or CaM in mediating AKAP150
association with TRPV1 in both cultured primary affer-
ent neurons and immortalized CHO cells. In cultured
TG, calcium influx inhibited AKAP150 association with
TRPV1, in a manner sensitive to pharmacological inhibi-
tion of CaM. Furthermore, CaM inhibition increased
PKA-directed sensitization of TRPV1, a process known
to be dependent upon functional AKAP150 association
[13,16,18,19]. Experiments that tested the effects of
CaM inhibition on TRPV1 activity in the presence of
calcineurin inhibitors suggest that the CaM-associated
protein calcineurin does not contribute to the reported
results. Finally, the co-expression of wtCaM or DNCaM
with AKAP150 and TRPV1 in the CHO model yielded
results that indicate that CaM alone is sufficient to
reduce functional association of the scaffolding protein
and receptor channel, using TIRF/FRET analysis, co-
immunoprecipitation, and electrophysiology. In light of
the general assumption that CaM plays a major role in
the desensitization of TRPV1, it may play a larger role
in preventing the resensitization of TRPV1 by blocking
AKAP150 association and subsequent phopshorylation
of the receptor channel.
In experimental results presented here, it is assumed
that CaM primarily associates with TRPV1. In fact,
AKAP79, the human ortholog to AKAP150, has demon-
strated an ability to also bind CaM in environments of
high calcium [33]. PKC and CaM compete for a similar
binding site on AKAP79, such that when intracellular
calcium increases and CaM is present, AKAP79 binds
the calcium/CaM complex and “releases” PKC from
neuronal post-synaptic densities to interact with other
proteins and participate in adjacent signaling events
[33]. The data presented here circumvent this theory, in
that it has been previously demonstrated that functional
expression of AKAP150 is required for PKC-mediated
phosphorylation and sensitization of TRPV1 [17,19].
Furthermore, the introduction of CaM via heterologous
expression in AKAP150- and TRPV1-expressing CHO
cells resulted in a significant reduction in TRPV1 activ-
ity. If CaM association with AKAP150 were significant
in this scheme, one would expect to observe increased
CAP-responses following CaM co-expression, since
TRPV1 activity is sensitive to PKC-mediated phosphory-
lation [8,10]. However, the results presented herein spe-
cifically demonstrate significantly reduced TRPV1
activities in the presence of CaM, indicating that the cal-
cium-sensitive molecule interferes with the association
of AKAP150 and TRPV1.
The deletion of CaM binding sites in the TRPV1
sequence provided interesting findings in our studies, in
the context of previously published studies using similar
Figure 6 Calmodulin co-expression decreases TRPV1 and
AKAP150 TIRF/FRET signal. (A) Images of CHO cells expressing
CFP-tagged TRPV1 and YFP-tagged AKAP150 and either wild-type
calmodulin (wtCaM) or dominant-negative calmodulin (DNCaM)
under TIFR illumination, using 442 or 514 nm laser lines. Images of
the CFP (in rainbow pseudocolor) and YFP (in yellow pseudocolor)
emissions are shown before or after YFP photobleach, as labelled.
(B) TIRF/FRET values from images acquired in A are quantified and
illustrated as percent increase in CFP emission cells expressing the
indicated calmodulin species. Vector = pcDNA3, mean ± SEM
shown. Significance determined by Student’s T-test, n = 9-12 cells/
transfection paradigm, *p < 0.05.
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amino acid C-terminal sequence of TRPV1 responsible
for binding CaM following rises in intracellular calcium.
The corresponding amino acids in the rat cDNA were
deleted (TRPV1ΔC CaM) for studies presented here.
We also created a TRPV1 mutant missing the N-
terminal CaM binding site (TRPV1ΔNC a M ) ,b a s e do n
previous reports [23,25]. In agreement with findings
reported by Rosenbaum et al. (2004), we demonstrate
that the presence of calcium/CaM significantly reduces
TRPV1 activity, in a manner that indicates channel
desensitization. Furthermore, we were able to
Figure 7 Calmodulin co-expression decreases TRPV1 and AKAP150 association. (A) Co-immunoprecipitation and Western blot analysis of
TRPV1 and AKAP150 from CHO cells co-expressing wt CaM or DN CaM. (B) Quantified densitometry of co-immunoprecipitation results
normalized to total TRPV1 expression. (C) CAP (100 nM, 30 sec) -current responses (100 nM, 30 sec) from CHO cells expressing AKAP150 and
TRPV1 with empty vector pcDNA3, wt CaM, or DN CaM, following vehicle (Veh, H20, gray bars) or 8-Br (8-Br-cAMP, 10 μm, 30 sec, black bars) pre-
treatment, n = 6-9 per transfection/treatment paradigm. Black asterisks indicate significance between indicated groups. Significance determined
by one-way ANOVA with Bonferroni correction, NS = no significance, *p < 0.05, ***p < 0.001. (D-F) Representative current traces from CHO cells
expressing AKAP150, TRPV1, and empty vector (D), wtCaM (E), or DNCaM (F).
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AKAP150 association with TRPV1 and subsequent
CAP-responses. However, others have been unable to
demonstrate that W-7 treatment can significantly block
CAP-directed tachyphylactic desensitization [20,34],
thereby suggesting that CaM may not associate with
TRPV1 as a free molecule, but rather as an associative
part of a calcium-sensitive complex.
The CaM binding sites of TRPV1 are required for
multiple signaling mechanisms that ensure channel
activity, nociceptor viability, and overall health and pro-
tection of the organism. In this study, we identify CaM
association with TRPV1 as a mechanism that prevents
AKAP150 association with and subsequent sensitization
of the receptor channel. Following the activation of
TRPV1 by a nociceptive stimulus, the influx of calcium
ions act to bind and activate CaM, which then associates
with TRPV1 [24,25]. The CaM complex formation with
TRPV1 effectively prohibits AKAP150 from associating
with TRPV1. It is this mechanism that is postulated to
prolong desensitization of the channel, as AKAP150
association with TRPV1 would allow for recovery from
its de-phosphorylated, desensitized state. The results
presented here may help to contribute to understanding
the various molecular mechanisms that contribute to
the specific states of TRPV1 channel desensitization fol-
lowing tachyphylaxis.
Methods
Tissue Culture
The Institutional Animal Care and Use Committee of
UTHSCSA has approved all procedures for the use of
animals, which were conducted in accordance with poli-
cies for the ethical treatment of animals established by
the National Institutes of Health. Trigeminal ganglia
(TG) were dissected bilaterally from male Sprague-Daw-
ley rats (200-250 g; Charles River Laboratories, Wil-
mington, MA) and dissociated by treatment with
collagenase (Lot# S5K8219, Worthington, Lakewood,
NJ) for 30 min, followed by treatment with trypsin
(Sigma, St. Louis, MO) for 15 min. Cells were centri-
fuged, aspirated and re-suspended in Dulbecco’sm o d i -
fied Eagle’s medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Invitrogen),
100 ng/ml nerve growth factor (Harlan Laboratories,
Indianapolis, IN), 1% penicillin/streptomycin (Invitro-
gen) and 1% glutamine (Sigma), and then placed on
poly-D-lysine coated plates. Cultures were maintained at
37°C and 5% CO2 and grown for 5-7 days. Chinese
hamster ovarian (CHO) cells were utilized for heterolo-
gous expression of cDNA constructs. CHO cells were
maintained in Dulbecco’s modified Eagle’sm e d i u m
(Cellgro, Mediatech Inc. Manassas, VA) with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA) along with 1%
penicillin (Invitrogen) and streptomycin (Invitrogen) at
37°C and 5% CO2. CHO ells were transiently transfected
with equal amounts of each cDNA per experiment,
using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions.
Crude plasma membrane preparation,
Immunoprecipitation and Western Blot Analysis
CHO cells and cultured TG were harvested as pre-
viously described [21]. W-7 (100 μM, 30 min treatment,
Sigma Aldrich), BAPTA-AM (1,2-bis(o-aminophenoxy)
ethane-N, N, N’,N ’-tetraacetic acid tetrakis(acetoxy-
methyl ester); 50 μM, 10 min treatment, Sigma Aldrich),
CAIP (calcineurin autoinhibitory peptide, [21], 100 μM,
30 min treatment, EMD Chemicals, Inc., Gibbstown, NJ)
or A23187 (1 μM,10 min treatment, Sigma Aldrich) was
used to treat the cells at 37°C prior to cell harvest. Fol-
lowing homogenization by 20 strokes in a Potter-Elveh-
jem homogenizer in a hypotonic homogenization buffer
(25 mM HEPES, 25 mM sucrose, 1.5 mM MgCl2, 50
mM NaCl, pH 7.2), the whole-cell homogenate was
incubated on ice for 15 min and then centrifuged at
1000 g for 1 min at 4°C to remove nuclei and unlysed
cells from the homogenate. The supernatant was iso-
l a t e da n dc e n t r i f u g e da t1 60 0 0gf o r3 0m i na t4 ° C ,
separating cytosolic proteins from cell membrane pro-
teins. The pellet (crude plasma membrane fraction) was
then re-suspended in 500 μL homogenization buffer
containing 1% Triton X-100 (Fisher Scientific, Pitts-
burgh, PA). The protein contents of crude plasma mem-
brane fractions were quantified using the Bradford assay
[35] as recommended by the manufacturer (Sigma). Fol-
lowing protein quantification, crude plasma membrane
fractions (200 μg) were incubated with 1 μgo fa n t i -
AKAP150 (R-300, Santa Cruz Biotechnology, Santa
Cruz, CA) or anti-TRPV1 (R-130, Santa Cruz Biotech-
nology) for 2 hr at 4°C. Samples were then centrifuged
at 16 0000 g for 1 min at 4°C to remove unsolubilized
material, and the supernatant was incubated with pro-
tein-A agarose beads (Sigma) for 1 hr at 4°C, followed
by 4 washes of the beads with homogenization buffer
containing 1% Triton. Immunoprecipitates were resolved
via 12.5% SDS-polyacrylamide and transferred to polyvi-
nyl difluoride membrane (Millipore, Billerica, MA) for
immunoblotting. Western blots were blocked in 5%
non-fat milk in Tris-buffered saline/Tween 20 and incu-
bated in anti-AKAP150 or anti-TRPV1, followed by the
appropriate horseradish peroxidase-conjugated second-
ary antisera (GE Healthcare, Piscataway, NJ). Enhanced
chemiluminescence (GE Healthcare) was used following
manufacturer’s instructions for visualization of antigen-
antibody binding.
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Rat TRPV1 cDNA (generously provided by David Julius)
was used for cloning of TRPV1ΔNCaM and
TRPV1ΔCCaM in pECFP-C1 vector. For both
TRPV1ΔNCaM and TRPV1ΔCCaM, the mutations were
performed using restriction enzymes Spe I site and
EcoR V sites, respectively. The forward (F) and reverse
(R) primers used for generating mutants TRPV1ΔNCaM
were identified as F- 5’-TTTACTAGTAATGGAGCA-
GATGTCCAGGC-3’ and R- 5’-AAAACTAGTCTG-
CTTCAGGCTGTCTGC-3’ and TRPV1ΔCCaM, F- 5’-
TTTGATATC CGAGATAGACATGCCACC-3’ and R-
5’-AAAGATATCACAGTTGCCTGGGTCCTCG-3’.A l l
mutants were generated by Quickchange mutagenesis
(Stratagene, La Jolla, CA), and all clones were verified
by DNA sequencing.
Calcium Imaging
CHO cells were transfected as outlined above (Tissue
Culture) with pEGFP-N1 (Clontech, Mountain View,
CA, to identify transfected cells) and cDNA vectors con-
taining inserts corresponding to rat TRPV1 (generously
provided by David Julius, UCSF, San Francisco, CA), rat
AKAP150 wt (generously provided by John D. Scott,
University of Washington, Seattle, WA), and TRPV1 ΔN
CaM and TRPV1 ΔC CaM. To measure intracellular
[Ca
+2] levels, the dye Fura-2 AM (2 μM; Molecular
Probes, Carlsbad, CA) was loaded for 30 min at 37°C
into cells in the presence of 0.05% Pluronic (Calbio-
chem). Fluorescence was detected with a Nikon Eclipse
TE 2000-U microscope fitted with a 20×/0.8 NA Fluor
objective. Fluorescence images from 340 nm and 380
nm excitation wavelengths were collected and analyzed
with the MetaFluor Software (MetaMorph, Web Univer-
sal Imaging Corporation, Downingtown, PA). To assess
for Ca
+2 accumulation following TRPV1 activation, cap-
saicin (CAP, 50 nM; Sigma Aldrich) was administered
for 30 sec followed by a 3 min wash with standard
extracellular solution buffer (SES, 140 mM NaCl, 5 mM
K C l ,2m MC a C l 2, 1 mM MgCl2, 10 mM D-(+)-glucose,
10 mM HEPES, Ph 7.4). The net change in Ca
+2
(ΔF340/380) was calculated by subtracting the basal
F340/380 Ca
+2 level (mean value collected for 60 s prior
to CAP addition) from the peak F340/380 Ca
+2 level
achieved after exposure to the CAP. When required, the
PKA activator 8-Br-cAMP (10 μM) was applied to the
cell for 30 sec prior to CAP administration. For each
transfection/treatment group, 54-96 cells were imaged,
statistical significance determined by one-way ANOVA
analysis, with Bonferroni correction as needed. Percent
desensitization determined by calculating the percent
difference of the second CAP response from the first for
each recorded trace.
Total internal reflection fluorescence microscopy (TIRF)
microscopy
Fluorescence emissions from enhanced cyan fluorescent
protein (CFP)-tagged AKAP150 or enhanced yellow
fluorescent protein (YFP)-tagged TRPV1 were collected
at room temperature using TIRF microscopy [36]. All
TIRF experiments were performed in the total internal
reflection fluorescence microscopy core facility housed
within the Department of Physiology, UTHSCSA. Fluor-
escence emissions were collected using an inverted
Nikon TE2000 microscope with through-the-lens
(prismless) TIRF imaging (Nikon). This system is
equipped with a vibration isolation system (Technical
Manufacturing, Peabody, MA) to minimize drift and
noise. Samples were viewed through a plan-Apo TIRF
60× oil-immersion high resolution (1.45 numerical aper-
ture) TIRF objective. Coupled to the microscope is a
laser light delivery system (Prairie Technologies, Middle-
ton, WI) consisting of a 40 mW argon laser outputting
488 and 514 nm lines and a 442 nm diode pumped
solid-state laser. The excitation light was selected with
an acoustic optical tunable filter, controlled by Meta-
Morph software. CFP and YFP emissions were simulta-
neously collected using the Dual-View chip splitter
(Optical Insights), equipped with a filter cube containing
HQ470 nm/30 m and HQ550 nm/30 m emission filters
for CFP and YFP emission, respectively, and a 505 nm
dichroic mirror for separation of emission wavelengths.
In this configuration, the microscope uses only a dual-
bandpass TIRF dichroic mirror to separate the excita-
tion and emission light, with no excitation filters in the
microscope cube. The TIRF angle was adjusted by eye
to give the signature TIRF illumination to the experi-
mental chamber. Fluorescence images were collected
and processed with a 16 bit, cooled charge-coupled
device camera (Cascade 512F; Roper Scientific, Tucson,
AZ) interfaced to a PC running MetaMorph software.
This camera uses a front-illuminated EMCCD with on-
chip multiplication gain. Images were collected (200-600
ms exposure time, adjusted to best exploit the dynamic
range of the camera without pixel saturation) immedi-
ately before and after photobleaching. Images were not
binned or filtered, with pixel size corresponding to a
square of 122 × 122 nm.
Fluorescence resonance energy transfer (FRET)
We used either the “acceptor photobleaching” (donor
dequenching) or “sensitized emission” method of evalu-
ating FRET efficiency. In the former, the emission of the
donor fluorophore is compared before and after photo-
bleaching of the acceptor [37]. YFP photobleaching was
performed using the 100 W mercury lamp of the micro-
scope, using a standard YFP filter cube. We find that
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cube is sufficient to photobleach >75% of the YFP fluor-
ophores, yet results in negligible photobleaching of the
CFP fluorophores. The following protocol was used: the
medium in the glass-bottomed dishes was exchanged
with Ringer’s solution that contained the following (in
mM): 160 NaCl, 5 KCl, 1 MgCl2, 2 mM CaCl2,a n d1 0
HEPES, pH 7.4 with NaOH. Cells were first examined
using the mercury lamp and standard CFP or YFP filter
cubes to find a suitable cell robustly expressing both
CFP- and YFP-tagged proteins. Under TIRF illumina-
tion, the focal plane used is critical, and was adjusted if
necessary immediately before each image acquisition to
obtain a sharp TIRF image. The focusing and cell-cen-
tering protocol resulted in CFP photobleaching of <1%.
TIRF images using 442 and 514 laser lines were
acquired before and after photobleaching of the YFP
fluorophores. %FRET was calculated as the percentage
increase in CFP emission after YFP photobleaching by
using the following formula: percent FRET = [(CFPpost
- CFPpre)/CFPpre] × 100, where CFPpost is CFP emis-
sion after YFP photobleaching, and CFPpre is CFP emis-
sion before YFP photobleaching. The percent FRET was
calculated by drawing regions of interest around the
entire area of the cell and subtracting the background in
a cell-free region for each image.
For measurement of TIRF/FRET using the “sensitized
emission” method, the sample was excited at 442 nm,
and CFP and YFP emission simultaneously collected
using the Dual-View/camera combination, where the
split sides of the camera chip will be referred to as the
CFP and the YFP channels, respectively. To quantify the
effective FRET efficiency for each experiment, we use
the “3-cube” method used by many investigators
[38-41], based on the formalism of Gordon et al. [42].
Our system does not use three physical “cubes,” but
rather the Dual-View; however, the principle, which we
outline here, is the same. To quantify the “bleed-
through” of the CFP emission into the YFP channel,
cells expressing only ECFP-M were excited at 442 nm,
and the image intensities of the cell on the CFP and
YFP channels quantified, yielding a ratio of YFP chan-
nel/CFP channel of 26%. By exciting cells only expres-
sing EYFP-M, we determined that the bleed-through of
YFP emission into the CFP channel is zero, as is the
excitation of CFP by 514 nm light. The direct excitation
of YFP at 442 nm is calculated as a ratio of YFP excita-
tion at 514 nm, and this was quantified using cells only
expressing EYFP-M, yielding a value of 4.3%. Thus, to
measure sensitized-emission FRET, the cells are sequen-
tially imaged under 442 and 514 nm laser lines under
TIRF. The intensity of the cell region in the YFP chan-
nel is first scaled down by 26% of the intensity of the
identical cell region in the CFP channel, to isolate the
YFP emission. The total YFP emission is then broken
down into that arising from direct excitation by the 442
nm light, and that from energy transfer from CFP. The
former is calculated by multiplying the 514 nm image in
the YFP channel by 4.3%, with the remainder thus
assumed due to FRET. We then calculate the ratio of
total YFP emission to that from direct excitation of YFP,
the “FRET ratio” (FR). The FR value is easily converted
to FRET efficiency (Eeff) using the following equation:
Eeff = (FR - 1) × (YFP,442/CFP,442), where YFP,442
and CFP,442 are the molar extinction coefficients for
YFP and CFP when excited at 442 nm. From their pub-
lished maximal molar extinction coefficients and known
excitation spectra of YFP and CFP [43], the YFP,442/
CFP,442 ratio was calculated to be 0.101, which is used
to convert the FR to FRET efficiency.
Electrophysiology
Recordings were made in whole-cell perforated patch
voltage clamp (holding potential (Vh) of -60 mV) config-
uration at 22-24°C from transfected CHO cells. Data
were acquired and analyzed using an Axopatch 200B
amplifier and pCLAMP 10.0 software (Molecular
Devices). Recording data were filtered at 0.5 kHz and
s a m p l e da t2k H z .A c c e s sr e s i s t a n c e( R s) was compen-
sated (40-80%) when appropriate up to the value of 13-
18 MW. Data were rejected when Rs changed >20% dur-
ing recording, leak currents were >50pA, or input resis-
tance was <200 MW. Currents were considered positive
when their amplitudes were 5-fold bigger than displayed
noise (in root mean square). Standard external solution
(SES) contained (in mM): 140 NaCl, 5 KCl, 2 CaCl2,1
MgCl2, 10 D-glucose and 10 HEPES, pH 7.4. The pip-
ette solution for the perforated patch configurations
consisted of (in mM): 140 KCl, 1 MgCl2, 10 HEPES pH
7.3 and 250 mg/ml amphotericin B (Sigma, St. Louis,
MO). Drugs were applied using a fast, pressure-driven
and computer controlled 8-channel system (ValveLink8;
AutoMate Scientific, San Francisco, CA).
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